The pharmaceutical value chain is experiencing significant market developments including substitution from generics, growth of para-pharmaceutical products, deregulation of retail constraints and market concentration, development of e-commerce, priority placed on prevention services and innovation in logistics solutions. In this fast-moving environment, a global leader asked us to work on its long-term strategy in France.
We issued clear recommendations on how to turn the business model towards the most attractive segments. We also delivered fact-based guidance on necessary investments, as well as possible divestments from non-core activities. We supported the executive committee with the necessary management presentation to the board.
